Takeda Pharmaceutical (TAK) Cash from Investing Activities Growth (3y) (2021 - 2026)
Powered by 
Analysis
Takeda Pharmaceutical (TAK) Cash from Investing Activities Growth (3y) (2021 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 643.26 Bn | 622.50 Bn | 17.26 Bn | 33.51% |
| 2 | AbbVie | 443.31 Bn | 436.74 Bn | 12.70 Bn | -51.98% |
| 3 | Merck | 364.74 Bn | 357.60 Bn | 12.21 Bn | 21.19% |
| 4 | Novartis Ag | 266.46 Bn | 258.77 Bn | 11.24 Bn | -47.89% |
| 5 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn | 27.70% |
| 6 | Sanofi | 52.33 Bn | 44.95 Bn | 10.79 Bn | - |
| 7 | Revolution Medicines | 43.79 Bn | 43.79 Bn | - | - |
| 8 | Incyte | 25.23 Bn | 20.69 Bn | 1.57 Bn | -91.04% |
| 9 | United Therapeutics | 21.67 Bn | 19.01 Bn | 683.80 Mn | 33.61% |
| 10 | Takeda Pharmaceutical | 2.61 Bn | -3.19 Bn | 5.10 Bn | 34.35% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 34.35% |
| Mar 31, 2026 | 51.85% |
| Dec 31, 2025 | -65.32% |
| Sep 30, 2025 | -18.36% |
| Jun 30, 2025 | 32.09% |
| Mar 31, 2025 | 45.90% |
| Dec 31, 2024 | -7.71% |
| Sep 30, 2024 | -19.00% |
| Jun 30, 2024 | -16.08% |
| Mar 31, 2024 | -177.28% |
| Dec 31, 2023 | -185.81% |
| Sep 30, 2023 | -98.30% |
| Jun 30, 2023 | -794.76% |
| Mar 31, 2023 | -105.48% |
| Sep 30, 2022 | 76.43% |
| Jun 30, 2022 | -114.52% |
| Mar 31, 2022 | -29.20% |
| Dec 31, 2021 | -276.34% |
| Sep 30, 2021 | -109.49% |
| Jun 30, 2021 | -60.12% |